Best of ASCO - 2014 Annual Meeting

 

Welcome

Plasma Cell Disorders

Hematologic Malignancies—Plasma Cell Dyscrasia

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
Combined use of two monoclonal antibodies in patients with systemic AL amyloidosis and cardiac involvement.

Amandeep Godara

8009

Contemporary therapy efficacy for high-risk multiple myeloma: A systematic review.

Afia Ashraf

e19536

Ixazomib and dexamethasone in high risk smoldering multiple myeloma: A clinical and correlative pilot study.

Sham Mailankody

8051

Ixazomib, lenalidomide, and dexamethasone for patients with POEMS syndrome.

Angela Dispenzieri

8019

Patient-reported outcomes (PROs) with ibrutinib-rituximab in Waldenström macroglobulinemia (WM): Results from iNNOVATE.

Alessandra Tedeschi

8018

Phase I trial of a novel DNA vaccine in patients (pts) with smoldering Waldenstrom macroglobulinemia (sWM).

Sheeba K. Thomas

8050

Prognosis of young patients with monoclonal gammopathy of undetermined significance.

Li Pang

8049

Safety and efficacy of four drug regimens in newly diagnosed multiple myeloma: Systematic review.

Udhayvir Singh Grewal

e19537

Seeking light-chain amyloidosis very early: The SAVE trial—identifying clonal lambda light chain genes in patients with MGUS or smoldering multiple myeloma.

Ping Zhou

8010

The frequency of chromosomal abnormalities in AL amyloidosis and their impact on treatment response.

Hassan Yameen

e19539

Venetoclax induces sustained complete responses in refractory/relapsed patients with cardiac AL amyloidosis.

Fabien Le Bras

e19538